In this edition

• Menopause Essentials Update
• Media release on PBS from AMS
• Menopausal Hormone Therapy (MHT) discontinuation and shortages March 2025
• AMS Webinar: After the IMS World Congress 2024 - Your queries, dilemmas and tricky questions answered archive
• Sleep and Menopause: new information and fact sheets from the AMS
• AMS Congress 2025 - Fremantle WA

Health Professionals - join AMS for Members-only content听

• Menopause Matters
• IMS Live 24 March 2025:听Age at menopause, obesity, and incident heart failure: The Atherosclerosis Risk in Communities Study
• European Menopause and Andropause Society (EMAS) Newsletter

In this edition

AMS News

This Menopause Essentials Update is designed as a wrap up of evidence-based management options for menopause and midlife health. Starting with structuring the initial consultation in the most effective way and finishing with a discussion of complex cases, the Menopause Essentials Update includes the latest on hormonal and non-hormonal options and up to date best-practice risk management recommendations across the full spectrum of menopause medicine.

Speakers include:听Dr Amie Hanlon,听Dr Christina Jang,听Dr Samantha Kerr, and Dr Hannah Farquhar.听

AMS applauds 2025 Commonwealth Budget announcements - media release

27 March 2025

The 草莓视频 (AMS) has welcomed the further health initiatives for midlife women as outlined in the 2025/2026 federal budget. Alongside the March 1, 2025, additions to the PBS, the Federal Government announced:

• $26.3 million for a new Medicare rebate for menopause health assessments
• $4.4 million investment over three years to develop national clinical guidelines and deliver professional development courses for health professionals
• $12.8 million for an awareness campaign relating to perimenopause and menopause

AMS Board President, Dr Sylvia Rosevear hopes that the Medicare rebate for health assessments will contribute to improving access for care for Australian midlife women, pending more details.

Dr Rosevear said, 鈥楤ecause of the complexity of menopause consultations, including individualising investigations and management, they take time. Now women have the opportunity to have quality attention from their healthcare professionals.鈥�

鈥楾he AMS commends funding to comprehensively train health professionals which should ensure that perimenopausal and menopausal patients receive a consistent approach from their medical advisors and are treated with the best evidence鈥揵ased care.

The creation of a national awareness campaign is a positive for all women and their families. A campaign will demystify menopause, and the health issues associated with both perimenopause and menopause.鈥�

Dr Rosevear concludes, 鈥楾he AMS looks forward to working alongside the Commonwealth Government on many of these measures, to increase health provider and patient awareness on the menopause pending further information. This investment into women鈥檚 health is truly pleasing in caring for perimenopausal and menopausal patients in all parts of Australia.鈥�

Menopausal Hormone Therapy (MHT) discontinuation and shortages March 2025

Australia听

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

听	Availability and expected supply due		Alternative supply under Section 19A
Dose	Estradot	Estraderm	Estramon	Estradiol Transdermal System
25听mcg	Limited - 31 Dec 2025	Limited - 30th June 2025	Available	听
37.5听mcg	Unavailable - 30th Jun 2025	听	Available	Available
50 mcg	Unavailable - 31st Dec 2025	Limited - 30th June 2025	Available	Unavailable
75 mcg	Unavailable - 31st Dec 2025	Unavailable - 30th June 2025	Available	Unavailable
100听mcg	Limited - 31st Dec 2025	Limited - 7th April 2025	Available	Available

Combined patches

Dose	Estalis Sequi	Estalis Conti
50/140	Limited 鈥� 30th June 2025	Unavailable 鈥� 30th June 2025
50/250	Limited听鈥� 30th June 2025	Limited 鈥� 30th June 2025

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 26^th March 2025, patch availability is provided below.

Dose	Estradot	Viatris	Estraderm MX
25mcg	Limited	Available听	Available
50mcg	Limited	Available	听
75mcg	Limited	Available	听
100mcg	Limited	Available	听

More information can be found听听听

The provides a guideline to approximately equivalent doses of the different MHT/HRT products in New Zealand.

AMS Webinar: After the IMS World Congress 2024 - Your queries, dilemmas and tricky questions answered

If you did not have the opportunity to attend the webinar the archive version (also with CPD points) will also be available shortly on听 听听

Sleep and Menopause: new information and fact sheets from the AMS

The 草莓视频 has added an information sheet for healthcare providers (Menopause and sleep), and a fact sheet for consumers (Suggested strategies to optimise sleep), on 鈥淪leep and Menopause鈥�.

These new resources for our website have been kindly written for the AMS by Dr Kerri Melehan, Senior Sleep Scientist, teacher of sleep medicine, and sleep researcher at Royal Prince Alfred Hospital and University of Sydney.

AMS Congress 2025 - Fremantle WA

Registration now open听

Health Professionals - join AMS for Members-only content听

Menopause Matters:听Professor Athol Kent has reviewes and comments on recent journal articles.

IMS Live 24 March 2025:听Age at menopause, obesity, and incident heart failure: The Atherosclerosis Risk in Communities Study

European Menopause and Andropause Society (EMAS) Newsletter听AMS is an affiliate of EMAS.听See latest copy.